Wedbush Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $40
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Laura Chico has maintained a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) and lowered the price target from $86 to $40.
July 20, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wedbush has maintained a Neutral rating on Apellis Pharmaceuticals and lowered the price target from $86 to $40.
The lowering of the price target by Wedbush from $86 to $40 indicates a negative outlook for Apellis Pharmaceuticals. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100